{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T17:05:14Z","timestamp":1753895114125,"version":"3.41.2"},"reference-count":26,"publisher":"Federa\u00e7\u00e3o das Associa\u00e7\u00f5es de Ginecologia e Obstetr\u00edcia","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,4,30]]},"DOI":"10.61622\/rbgo\/2025rbgo13","type":"journal-article","created":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T16:47:19Z","timestamp":1747241239000},"source":"Crossref","is-referenced-by-count":0,"title":["Evaluation of pathological complete response rates in breast cancer patients undergoing neoadjuvant therapy"],"prefix":"10.61622","volume":"47","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-0972-0372","authenticated-orcid":false,"given":"Gabriella","family":"Ferezini Oliveira de S\u00e1","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9504-8589","authenticated-orcid":false,"given":"Pedro Vilar de Oliveira","family":"Villarim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-2771-4242","authenticated-orcid":false,"given":"Pedro Hort\u00eancio","family":"Saboia da Escossia Melo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9131-1952","authenticated-orcid":false,"given":"Ayane Cristine Alves","family":"Sarmento","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8351-5119","authenticated-orcid":false,"given":"Ana Katherine","family":"Gon\u00e7alves","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4105-7535","authenticated-orcid":false,"given":"Kleyton","family":"Santos de Medeiros","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9301-7917","authenticated-orcid":false,"given":"Cristina","family":"Rocha de Medeiros Miranda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"47794","reference":[{"issue":"4","key":"key20250514164711_B1","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1002\/ijc.33588","article-title":"Cancer statistics for the year 2020: an overview","volume":"149","author":"Ferlay","year":"2021","unstructured":"1 Ferlay J, Colombet M, Soerjomataram I, Parkin DM, Pi\u00f1eros M, Znaor A, et al. Cancer statistics for the year 2020: an overview. Int J Cancer. 2021;149(4):778-89. doi: 10.1002\/ijc.33588","journal-title":"Int J Cancer"},{"key":"key20250514164711_B2","doi-asserted-by":"crossref","first-page":"101823","DOI":"10.1016\/j.suronc.2022.101823","article-title":"Feasibility of targeted axillary dissection for de-escalation of surgical treatment after neoadjuvant chemotherapy in breast cancer","volume":"44","author":"Arag\u00f3n-S\u00e1nchez","year":"2022","unstructured":"2 Arag\u00f3n-S\u00e1nchez S, Ciruelos-Gil E, L\u00f3pez-Mar\u00edn L, Galindo A, Tabuenca-Mateos MJ, Jim\u00e9nez-Arranz S, et al. Feasibility of targeted axillary dissection for de-escalation of surgical treatment after neoadjuvant chemotherapy in breast cancer. Surg Oncol. 2022;44:101823. doi: 10.1016\/j.suronc.2022.101823","journal-title":"Surg Oncol"},{"issue":"11","key":"key20250514164711_B3","doi-asserted-by":"crossref","first-page":"5960","DOI":"10.1245\/s10434-021-09897-w","article-title":"Factors associated with nodal pathologic complete response among breast cancer patients treated with neoadjuvant chemotherapy: results of calgb 40601 (HER2+) and 40603 (Triple-Negative) (Alliance)","volume":"28","author":"Weiss","year":"2021","unstructured":"3 Weiss A, Campbell J, Ballman KV, Sikov WM, Carey LA, Hwang ES, et al. Factors associated with nodal pathologic complete response among breast cancer patients treated with neoadjuvant chemotherapy: results of calgb 40601 (HER2+) and 40603 (Triple-Negative) (Alliance). Ann Surg Oncol. 2021;28(11):5960-71. doi: 10.1245\/s10434-021-09897-w","journal-title":"Ann Surg Oncol"},{"issue":"5","key":"key20250514164711_B4","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1634\/theoncologist.2018-0228","article-title":"Neoadjuvant management of early breast cancer: a clinical and investigational position statement","volume":"24","author":"Colomer","year":"2019","unstructured":"4 Colomer R, Saura C, S\u00e1nchez-Rovira P, Pascual T, Rubio IT, Burgu\u00e9s O, et al. Neoadjuvant management of early breast cancer: a clinical and investigational position statement. Oncologist. 2019;24(5):603-11. doi: 10.1634\/theoncologist.2018-0228","journal-title":"Oncologist"},{"key":"key20250514164711_B5","doi-asserted-by":"crossref","DOI":"10.1177\/1758835919827714","article-title":"Post-neoadjuvant treatment and the management of residual disease in breast cancer: state of the art and perspectives","volume":"11","author":"Caparica","year":"2019","unstructured":"5 Caparica R, Lambertini M, Pond\u00e9 N, Fumagalli D, de Azambuja E, Piccart M. Post-neoadjuvant treatment and the management of residual disease in breast cancer: state of the art and perspectives. Ther Adv Med Oncol. 2019;11:1758835919827714. doi: 10.1177\/1758835919827714","journal-title":"Ther Adv Med Oncol"},{"issue":"9938","key":"key20250514164711_B6","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/S0140-6736(13)62422-8","article-title":"Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis","volume":"384","author":"Cortazar","year":"2014","unstructured":"6 Cortazar P, Zhang L, Untch M, Mehta K, Costantino JP, Wolmark N, et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet. 2014;384(9938):164-72. doi: 10.1016\/S0140-6736(13)62422-8","journal-title":"Lancet"},{"key":"key20250514164711_B7","doi-asserted-by":"crossref","first-page":"106280","DOI":"10.1016\/j.cct.2021.106280","article-title":"Bayesian decision making in confirmatory early-stage breast cancer trial","volume":"102","author":"Gu","year":"2021","unstructured":"7 Gu E, Zhou X, Zhao J. Bayesian decision making in confirmatory early-stage breast cancer trial. Contemp Clin Trials. 2021;102:106280. doi: 10.1016\/j.cct.2021.106280","journal-title":"Contemp Clin Trials"},{"key":"key20250514164711_B8","article-title":"Evaluation of pathological complete response as surrogate endpoint in neoadjuvant randomised clinical trials of early stage breast cancer: systematic review and meta-analysis","volume":"375","author":"Conforti","year":"2021","unstructured":"8 Conforti F, Pala L, Sala I, Oriecuia C, De Pas T, Specchia C, et al. Evaluation of pathological complete response as surrogate endpoint in neoadjuvant randomised clinical trials of early stage breast cancer: systematic review and meta-analysis. BMJ. 2021;375:e066381. doi: 10.1136\/bmj2021-066381","journal-title":"BMJ"},{"key":"key20250514164711_B9","doi-asserted-by":"crossref","first-page":"S137","DOI":"10.1016\/S0960-9776(09)70289-9","article-title":"Lessons on responsiveness to adjuvant systemic therapies learned from the neoadjuvant setting","volume":"18","author":"Colleoni","year":"2009","unstructured":"9 Colleoni M, Viale G, Goldhirsch A. Lessons on responsiveness to adjuvant systemic therapies learned from the neoadjuvant setting. Breast. 2009;18 Suppl 3:S137-40. doi: 10.1016\/S0960-9776(09)7028","journal-title":"Breast"},{"issue":"3","key":"key20250514164711_B10","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1093\/jjco\/hyz213","article-title":"Adjuvant and neoadjuvant therapy for breast cancer","volume":"50","author":"Shien","year":"2020","unstructured":"10 Shien T, Iwata H. Adjuvant and neoadjuvant therapy for breast cancer. Jpn J Clin Oncol. 2020;50(3):225-9. doi: 10.1093\/jjco\/hyz213","journal-title":"Jpn J Clin Oncol"},{"issue":"1","key":"key20250514164711_B11","doi-asserted-by":"crossref","first-page":"238","DOI":"10.3390\/ijerph18010238","article-title":"Influence of public oral health services and socioeconomic indicators on the frequency of hospitalization and deaths due to oral cancer in Brazil, between 2002-2017","volume":"18","author":"Freire","year":"2020","unstructured":"11 Freire AR, Freire DE, Ara\u00fajo EC, de Lucena EH, Cavalcanti YW. Influence of public oral health services and socioeconomic indicators on the frequency of hospitalization and deaths due to oral cancer in Brazil, between 2002-2017. Int J Environ Res Public Health. 2020;18(1):238. doi: 10.3390\/ijerph18010238","journal-title":"Int J Environ Res Public Health"},{"issue":"10","key":"key20250514164711_B12","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.0040297","article-title":"Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration","volume":"4","author":"Vandenbroucke","year":"2007","unstructured":"12 Vandenbroucke JP, von Elm E, Altman DG, G\u00f8tzsche PC, Mulrow CD, Pocock SJ, et al. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration. PLoS Med. 2007;4(10):e297. doi: 10.1371\/journal.pmed.0040297","journal-title":"PLoS Med"},{"issue":"3","key":"key20250514164711_B13","doi-asserted-by":"crossref","first-page":"324","DOI":"10.6004\/jnccn.2016.0037","article-title":"Invasive breast cancer version 1.2016, NCCN Clinical Practice Guidelines in Oncology","volume":"14","author":"Gradishar","year":"2016","unstructured":"13 Gradishar WJ, Anderson BO, Balassanian R, Blair SL, Burstein HJ, Cyr A, et al. Invasive breast cancer version 1.2016, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2016;14(3):324-54. doi: 10.6004\/jnccn.2016.0037","journal-title":"J Natl Compr Canc Netw"},{"issue":"3","key":"key20250514164711_B14","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1093\/jnci\/dji021","article-title":"Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis","volume":"97","author":"Mauri","year":"2005","unstructured":"14 Mauri D, Pavlidis N, Ioannidis JP. Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis. J Natl Cancer Inst. 2005;97(3):188-94. doi: 10.1093\/jnci\/dji021","journal-title":"J Natl Cancer Inst"},{"key":"key20250514164711_B15","doi-asserted-by":"crossref","first-page":"898","DOI":"10.3332\/ecancer.2019.898","article-title":"Access to high-cost drugs for advanced breast cancer in Latin America, particularly trastuzumab","volume":"13","author":"Barrios","year":"2019","unstructured":"15 Barrios CH, Reinert T, Werutsky G. Access to high-cost drugs for advanced breast cancer in Latin America, particularly trastuzumab. Ecancermedicalscience. 2019;13:898. doi: 10.3332\/ecancer.2019.898","journal-title":"Ecancermedicalscience"},{"issue":"4","key":"key20250514164711_B16","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1590\/S1679-45082013000400007","article-title":"Neoadjuvant chemotherapy and pathologic response: a retrospective cohort","volume":"11","author":"Andrade","year":"2013","unstructured":"16 Andrade DA, Zucca-Matthes G, Vieira RA, Andrade CT, Costa AM, Monteiro AJ, et al. Neoadjuvant chemotherapy and pathologic response: a retrospective cohort. Einstein (Sao Paulo). 2013;11(4):446-50. doi: 10.1590\/s1679-45082013000400007","journal-title":"Einstein (Sao Paulo)"},{"key":"key20250514164711_B17","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.ejca.2022.09.017","article-title":"Pathological complete response rate and disease-free survival after neoadjuvant chemotherapy in patients with HER2-low and HER2-0 breast cancers","volume":"176","author":"De Nonneville","year":"2022","unstructured":"17 De Nonneville A, Houvenaeghel G, Cohen M, Sabiani L, Bannier M, Viret F, Pathological complete response rate and disease-free survival after neoadjuvant chemotherapy in patients with HER2-low and HER2-0 breast cancers. Eur J Cancer. 2022;176:181-8. doi: 10.1016\/j.ejca.2022.09.017","journal-title":"Eur J Cancer"},{"issue":"9","key":"key20250514164711_B18","doi-asserted-by":"crossref","first-page":"963","DOI":"10.3109\/07357907.2010.496759","article-title":"Population-based estimate of the prevalence of HER-2 positive breast cancer tumors for early stage patients in the US","volume":"28","author":"Cronin","year":"2010","unstructured":"18 Cronin KA, Harlan LC, Dodd KW, Abrams JS, Ballard-Barbash R. Population-based estimate of the prevalence of HER-2 positive breast cancer tumors for early stage patients in the US. Cancer Invest. 2010;28(9):963-8. doi: 10.3109\/07357907.2010.496759","journal-title":"Cancer Invest"},{"issue":"26","key":"key20250514164711_B19","doi-asserted-by":"crossref","first-page":"3242","DOI":"10.1200\/JCO.2011.39.2779","article-title":"Pathologic complete response predicts recurrence-free survival more effectively by cancer subset: results from the I-SPY 1 TRIAL--CALGB 150007\/150012, ACRIN 6657","volume":"30","author":"Esserman","year":"2012","unstructured":"19 Esserman LJ, Berry DA, DeMichele A, Carey L, Davis SE, Buxton M, et al. Pathologic complete response predicts recurrence-free survival more effectively by cancer subset: results from the I-SPY 1 TRIAL--CALGB 150007\/150012, ACRIN 6657. J Clin Oncol. 2012;30(26):3242-9. doi: 10.1200\/JCO.2011.39.2779","journal-title":"J Clin Oncol"},{"issue":"16","key":"key20250514164711_B20","doi-asserted-by":"crossref","first-page":"2998","DOI":"10.1200\/JCO.22.02241","article-title":"Pathologic complete response and individual patient prognosis after neoadjuvant chemotherapy plus anti-human epidermal growth factor receptor 2 therapy of human epidermal growth factor receptor 2-positive early breast cancer","volume":"41","author":"Van Mackelenbergh","year":"2023","unstructured":"20 Van Mackelenbergh MT, Loibl S, Untch M, Buyse M, Geyer CE Jr, Gianni L, et al. Pathologic complete response and individual patient prognosis after neoadjuvant chemotherapy plus anti-human epidermal growth factor receptor 2 therapy of human epidermal growth factor receptor 2-positive early breast cancer. J Clin Oncol. 2023;41(16):2998-3008. doi: 10.1200\/JCO.22.02241","journal-title":"J Clin Oncol"},{"issue":"24","key":"key20250514164711_B21","doi-asserted-by":"crossref","first-page":"5427","DOI":"10.1158\/0008-5472.CAN-20-1792","article-title":"Association of pathologic complete response with long-term survival outcomes in triple-negative breast cancer: a meta-analysis","volume":"80","author":"Huang","year":"2020","unstructured":"21 Huang M, O\u2019Shaughnessy J, Zhao J, Haiderali A, Cort\u00e9s J, Ramsey SD, et al. Association of pathologic complete response with long-term survival outcomes in triple-negative breast cancer: a meta-analysis. Cancer Res. 2020;80(24):5427-34. doi: 10.1158\/0008-5472.CAN-20-1792","journal-title":"Cancer Res"},{"issue":"4","key":"key20250514164711_B22","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1097\/SLA.0000000000002953","article-title":"The clinical significance of breast-only and node-only Pathologic Complete Response (pCR) After Neoadjuvant Chemotherapy (NACT): a review of 20,000 breast cancer patients in the National Cancer Data Base (NCDB)","volume":"268","author":"Fayanju","year":"2018","unstructured":"22 Fayanju OM, Ren Y, Thomas SM, Greenup RA, Plichta JK, Rosenberger LH, et al. The clinical significance of breast-only and node-only Pathologic Complete Response (pCR) After Neoadjuvant Chemotherapy (NACT): a review of 20,000 breast cancer patients in the National Cancer Data Base (NCDB). Ann Surg. 2018;268(4):591-601. doi: 10.1097\/SLA.0000000000002953","journal-title":"Ann Surg"},{"issue":"12","key":"key20250514164711_B23","doi-asserted-by":"crossref","first-page":"2838","DOI":"10.1158\/1078-0432.CCR-19-3492","article-title":"Pathologic complete response after neoadjuvant chemotherapy and impact on breast cancer recurrence and survival: a comprehensive meta-analysis","volume":"26","author":"Spring","year":"2020","unstructured":"23 Spring LM, Fell G, Arfe A, Sharma C, Greenup R, Reynolds KL, et al. Pathologic complete response after neoadjuvant chemotherapy and impact on breast cancer recurrence and survival: a comprehensive meta-analysis. Clin Cancer Res. 2020;26(12):2838-48. doi: 10.1158\/1078-0432.CCR-19-3492","journal-title":"Clin Cancer Res"},{"key":"key20250514164711_B24","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1002\/cncr.32887","article-title":"Breast cancer early detection: a phased approach to implementation","volume":"126","author":"Ginsburg","year":"2020","unstructured":"24 Ginsburg O, Yip CH, Brooks A, Cabanes A, Caleffi M, Dunstan Yataco JA, et al. Breast cancer early detection: a phased approach to implementation. Cancer. 2020;126 Suppl 10:2379-93. doi: 10.1002\/cncr.32887","journal-title":"Cancer"},{"key":"key20250514164711_B25","doi-asserted-by":"crossref","first-page":"101970","DOI":"10.1016\/j.canep.2021.101970","article-title":"Breast cancer in Brazil: screening program and surgical approach","volume":"73","author":"Nascimento","year":"2021","unstructured":"25 Nascimento JH, Vieira AT, Souza Filho BM, Tomaz SC, Delgado Bocanegra RE, Melo Costa VS, et al. Breast cancer in Brazil: screening program and surgical approach. Cancer Epidemiol. 2021;73:101970. doi: 10.1016\/j.canep.2021.101970","journal-title":"Cancer Epidemiol"},{"issue":"9","key":"key20250514164711_B26","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1016\/S1470-2045(15)00128-X","article-title":"Effect of mammographic screening from age 40 years on breast cancer mortality in the UK Age trial at 17 years\u2019 follow-up: a randomised controlled trial","volume":"16","author":"Moss","year":"2015","unstructured":"26 Moss SM, Wale C, Smith R, Evans A, Cuckle H, Duffy SW. Effect of mammographic screening from age 40 years on breast cancer mortality in the UK Age trial at 17 years\u2019 follow-up: a randomised controlled trial. Lancet Oncol. 2015;16(9):1123-32. doi: 10.1016\/S1470-2045(15)00128-X","journal-title":"Lancet Oncol"}],"container-title":["Revista Brasileira de Ginecologia e Obstetr\u00edcia"],"original-title":[],"language":"en","deposited":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T16:47:23Z","timestamp":1747241243000},"score":1,"resource":{"primary":{"URL":"https:\/\/journalrbgo.org\/pt-br\/article\/evaluation-of-pathological-complete-response-rates-in-breast-cancer-patients-undergoing-neoadjuvant-therapy\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":26,"alternative-id":["10.61622\/rbgo\/2025rbgo13"],"URL":"https:\/\/doi.org\/10.61622\/rbgo\/2025rbgo13","relation":{},"ISSN":["0100-7203","1806-9339"],"issn-type":[{"type":"print","value":"0100-7203"},{"type":"electronic","value":"1806-9339"}],"subject":[],"published":{"date-parts":[[2025]]},"article-number":"e-rbgo13"}}